Drug Profile
SB 728 T
Alternative Names: CCR5-ZFN; SB 728mR T; SB-728-modified-T-cells; SB-728-T; SB-728-T-CCR5-gene-therapy; ZFP TherapeuticLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Developer Sangamo Therapeutics
- Class Antivirals; Cell therapies; Gene therapies; T lymphocyte cell therapies; Zinc finger DNA binding proteins
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - HIV infections
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Dec 2020 Discontinued - Phase-II for HIV infections in USA, Puerto Rico (IV)
- 12 Jun 2019 Case Western Reserve University initiates enrolment in the TRAILBLAZER phase I/II trial for HIV infections in USA (NCT03666871)
- 04 Mar 2019 Additional efficacy and adverse events data from a phase I trial in HIV infections presented at the 26th Conference on Retroviruses and Opportunistic Infections (CROI-2019)